NOTICE IS HEREBY GIVEN that the 2023 annual general meeting of NUTRYFARM INTERNATIONAL LIMITED (the "**Company**") will be held at 8 Marina Boulevard, #29-01, Marina Bay Financial Centre Tower 1, Singapore 018981 on Tuesday, 31 March 2026 at 10.30 a.m. (Singapore time) and any adjournment thereof (the "**Annual General Meeting**") for the following purposes:

AS ORDINARY BUSINESS

To consider and if thought fit, to pass the following resolutions as Ordinary Resolutions, with or without any modifications:

1. To receive and adopt the Judicial Manager's Statement and audited financial statements of the Company for the financial period ended 30 September 2023 together with the auditor's report thereon. **(Resolution 1)**

2. To re-elect the following Directors of the Company, who will be retiring by rotation pursuant to Article 104 of the constitution of the company (the "**Constitution**"), and who, being eligible, offer themselves for re-election:

   (a) Mr Niu Liming *[see Explanatory Note (1)]* **(Resolution 2)**
   (b) Mr Er Kwong Wah *[see Explanatory Note (2)]* **(Resolution 3)**

3. To re-elect the following Directors of the Company, who will cease to hold office pursuant to Article 107A of the Constitution, and who, being eligible, offer themselves for re-election:

   (a) Mr Timothy John Goodchild *[see Explanatory Note (3)]* **(Resolution 4)**
   (b) Ms Ng Chern Nee *[see Explanatory Note (4)]* **(Resolution 5)**

4. To appoint Mr Wan Tai Foong as a Director of the Company. *[see Explanatory Note (5)]* **(Resolution 6)**

5. To re-appoint Nexia Singapore PAC ("**Nexia**"), Public Accountants and Chartered Accountants, as the Company's auditor, to hold office until the close of the next annual general meeting of the Company, at a fee to be agreed between the Company and Nexia. **(Resolution 7)**

6. To transact any other ordinary business which may properly be transacted at an annual general meeting.

BY ORDER OF THE BOARD

Niu Liming
Chief Executive Officer and Executive Director
10 March 2026

Explanatory Notes:

1. Ordinary Resolution 2 is to re-elect Mr Niu Liming, who will be retiring by rotation pursuant to Article 104 of the Constitution. Mr Niu will, upon re-election, remain as Chief Executive Officer and Executive, Non-Independent Director of the Company.

2. Ordinary Resolution 3 is to re-elect Mr Er Kwong Wah, who will be retiring by rotation pursuant to Article 104 of the Constitution. Mr Er will, upon re-election, remain as Non-Executive, Independent Director of the Company.

3. Ordinary Resolution 4 is to re-elect Mr Timothy John Goodchild, who will cease to hold office pursuant to Article 107A of the Constitution. Mr Goodchild will, upon re-election, remain as Non-Executive, Independent Director of the Company.

4. Ordinary Resolution 5 is to re-elect Ms Ng Chern Nee, who will cease to hold office pursuant to Article 107A of the Constitution. Ms Ng will, upon re-election, remain as Non-Executive, Independent Director of the Company.

5. Ordinary Resolution 6 is to appoint Mr Wan Tai Foong as a Director of the Company pursuant to Article 107 of the Constitution. Mr Wan will, upon his appointment, be designated as Non-Executive, Independent Director of the Company and Chairman of the Audit Committee. The Board considers Mr Wan to be independent for the purposes of the Listing Manual of the Singapore Exchange Securities Trading Limited. Mr Wan does not have any relationships, including immediate family relationships, with any of the Directors, the Company or its substantial shareholders.

Important Notes:

1. The 2023 Annual General Meeting will be held in a wholly physical format at 8 Marina Boulevard, #29-01, Marina Bay Financial Centre Tower 1, Singapore 018981 on Tuesday, 31 March 2026 at 10.30 a.m. (Singapore time). **There will be no option for the members to participate virtually**. Shareholders, including CPFIS and SRS investors who hold SGX shares through CPF Agent Banks or SRS Operators, and (where applicable) duly appointed proxies and representatives will be able to ask questions and vote at the 2023 Annual General Meeting by attending the physical meeting.

   Printed copies of this notice and the accompanying proxy form will be sent by post to members. These documents have also been made available on SGX website at the URL https://www.sgx.com/securities/company-announcements ("**SGXNet**").

2. Submission of Questions: Members who have any substantial and relevant questions in relation to any agenda item of this notice must submit their questions in writing to the Company in advance in the following manner:

   a) If submitted by post, be lodged at the office of Singapore Share Transfer Agent, Boardroom Corporate & Advisory Services Pte. Ltd., 1 Harbourfront Avenue, #14-07 Keppel Bay Tower, Singapore 098632; or

   b) if submitted electronically, be submitted via email to the Company's Share Transfer Agent, Boardroom Corporate & Advisory Services Pte. Ltd. at srs.proxy@boardroomlimited.com in either case, in advance of the AGM, no later than 17 March 2026 at 5.00 p.m.

Shareholders, including CPFIS Investors and SRS Investors, who submit questions via e-mail or by post to the Company's Share Transfer Agent must provide the following information:

(a) the Shareholder's full name;
(b) the Shareholder's full address; and
(c) the manner in which the Shareholder holds shares in NUTRYFARM INTERNATIONAL LIMITED (e.g. via CPFIS or SRS).

The Company will endeavour to upload the Company's responses to substantial and relevant questions from members on the SGXNet website by 19 March 2026.

3. Submission of Proxy Forms: Relevant Proxy Form(s) must be submitted to the Company in the following manner:

   a) If submitted by post, be lodged at the office of Singapore Share Transfer Agent, Boardroom Corporate & Advisory Services Pte. Ltd., 1 Harbourfront Avenue, #14-07 Keppel Bay Tower, Singapore 098632; or

   b) if submitted electronically, be submitted via email to the Company's Share Transfer Agent, Boardroom Corporate & Advisory Services Pte. Ltd. at srs.proxy@boardroomlimited.com

   in either case, no later than 10.30 a.m. on 29 March 2026 (the "**Proxy Deadline**").

4. A Depositor who is not an individual can only be represented at the Annual General Meeting if its nominee is/are appointed as CDP's proxy/proxies. To appoint its nominee/nominees as proxy/proxies of CDP and to enable its nominee/nominees to attend and vote at the Annual General Meeting, such Depositor should complete, execute and deposit the Depositor Proxy Form in accordance with the instructions at the Annual General Meeting.

5. A corporation which is a Shareholder may authorise by resolution of its directors or other governing body such person as it thinks fit to act as its corporate representative at the Annual General Meeting.

6. To be valid, the Shareholder Proxy Form or the Depositor Proxy Form, together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power or authority, must be deposited at the office of Singapore Share Transfer Agent, Boardroom Corporate & Advisory Services Pte. Ltd. at 1 Harbourfront Avenue, #14-07 Keppel Bay Tower, Singapore 098632 not less than forty-eight (48) hours before the time appointed for holding the Annual General Meeting or at any adjournment thereof. Detailed instructions can be found on the Shareholder Proxy Form and Depositor Proxy Form.

7. By submitting an instrument appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the Annual General Meeting and/or any adjournment thereof, a Shareholder of the Company (i) consents to the collection, use and disclosure of the Shareholder's personal data by the Company (or its agents or service providers) for the purpose of the processing, administration and analysis by the Company (or its agents or service providers) of proxies and representatives appointed for the Annual General Meeting

(including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the Annual General Meeting (including any adjournment thereof), and in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "**Purposes**"), (ii) warrants that where the Shareholder discloses the personal data of the Shareholder's proxy(ies) and/or representative(s) to the Company (or its agents or service providers), the Shareholder has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) and/or representative(s) for the Purposes, and (iii) agrees that the Shareholder will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the Shareholder's breach of warranty.

SGX Group

Mainboard Rules

Appendices

Appendix 7.4.1 Announcement of Appointment

Cross-referenced from Rule 210(5)(d) and Rule 704(7)

Date of Appointment

Date of last re-appointment (if applicable)

NA

Name of person

Wan Tai Foong

Age

57

Country of principal residence

Singapore

The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process).

The Board has approved the appointment of Mr Wan Tai Foong ("Mr Wan") as an Independent Non-Executive Director of NutryFarm International Limited (the "Company") based on an assessment of his qualifications and experience and is satisfied that Mr Wan has the requisite capabilities to assume the role and responsibilities of an Independent Non-Executive Director of the Company.

Whether appointment is executive, and if so, the area of responsibility

Non-Executive

Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)

Independent Non-Executive Director

Professional qualifications

CPA Australia - Member
Murdoch University - Bachelor of Commerce

Working experience and occupation(s) during the past 10 years

Qi Capital Pte Ltd - Chief Executive Officer

Shareholding interest in the listed issuer and its subsidiaries

No

Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries

No

Conflict of interest (including any competing business)

No

Undertaking (in the format set out in Appendix 7.7) under Rule 720(1) has been submitted to the listed issuer ■Yes☐No

Yes

Other Principal Commitments* Including Directorships#

* "Principal Commitments" has the same meaning as defined in the Code.

These fields are not applicable for announcements of appointments pursuant to Listing Rule 704(9)

Past (for the last 5 years)

OneApex Limited

Present

Qi Capital Pte Ltd
New Toyo International Holdings Ltd
ASTI Holdings Limited

Information required

Disclose the following matters concerning an appointment of director, chief executive officer, chief financial officer, chief operating officer, general manager or other officer of equivalent rank. If the answer to any question is "yes", full details must be given.

(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?	☐ Yes	■ **No**
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?	☐ Yes	■ **No**
(c) Whether there is any unsatisfied judgment against him?	☐ Yes	■ **No**
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?	☐ Yes	■ **No**
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?	☐ Yes	■ **No**
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?	☐ Yes	■ **No**
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?	☐ Yes	■ **No**

(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?	☐ Yes	■ **No**
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?	☐ Yes	■ **No**
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :—		
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or **Yes. Around year 1999-2000, Mr Wan was working for the Independent Financial Advisor ("IFA") to Liang Court Holdings Ltd ("Liang Court") in relation to the takeover offer by Somerset Land Pte Ltd. Mr Wan assisted in the MAS investigation in relation to the late despatch of the circular to shareholders for the takeover offer. Mr Wan and the IFA were not the subjects of the MAS investigation.**	■ **Yes**	☐ No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or	☐ Yes	■ **No**
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or	☐ Yes	■ **No**
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere,	☐ Yes	■ **No**
in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?		
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?	☐ Yes	■ **No**

Information required

Disclosure applicable to the appointment of Director only.

Any prior experience as a director of an issuer listed on the Exchange?	■ **Yes**	☐ No

If yes, please provide details of prior experience.

Independent Non-Executive Director of New Toyo International Holdings Ltd
Independent Non-Executive Director ASTI Holdings Limited

If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange.

N/A

Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable).

N/A

Amended on 29 September 2011, 7 October 2015, 1 January 2019 and 1 January 2022.